Study
| Phase 3, multicenter, randomized, double-blind trial (CABO-NET) |
| Advanced progressive neuroendocrine tumors (NETs) of the pancreas, lung, or gastrointestinal tract |
| Cabozantinib vs. placebo |
Efficacy
| mPFS: 8.4 mos vs. 3.9 mos (cabozantinib vs. placebo) (HR: 0.38 [0.25-0.59], P<0.001) (extrapancreatic NETs) |
| mPFS: 13.8 mos vs. 4.4 mos (cabozantinib vs. placebo) (HR: 0.23 [0.12-0.42], P<0.001) (pancreatic NETs) |
| ORR: 5% vs. 0% (extrapancreatic NETs) |
| ORR: 19% vs. 0% (pancreatic NETs) |
Safety
| Grade ≥3 AEs: Hypertension (28% vs. 6%), fatigue (22% vs. 8%), diarrhea (19% vs. 5%) |
| Serious AEs: 38% vs. 22% |
N Engl J Med 2025;392:653-65
Chan JA,Geyer S,Zemla T Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors
http://doi.org/10.1056/NEJMoa2400123
Reviewed by Ulas D. Bayraktar, MD on Mar 28, 2025
